Travere Therapeutics Inc (TVTX) - News Archive

SAN DIEGO, May 15, 2024 - Travere Therapeutics, Inc. (NASDAQ: TVTX) has recently disclosed the granting of inducement equity grants to several new employees, a move aimed at attracting top talent to fuel the growth and...

In recent years, sparsentan, marketed as FILSPARI, has emerged as a promising treatment for IgA nephropathy (IgAN). Travere Therapeutics, the biopharmaceutical company behind FILSPARI, recently presented groundbreaking...

Travere Therapeutics and CSL Vifor Advance Treatment for IgA Nephropathy with EC Approval of FILSPARI (sparsentan): A Major Milestone in Non-Immunosuppressive TherapyIn a significant breakthrough for patients living wit...

Travere Therapeutics, Inc. recently disclosed the issuance of inducement equity grants to four newly hired employees. This move aligns with the company s compensation strategy and complies with Nasdaq Listing Rule 5635(...

Travere Therapeutics Aims for Full FDA Approval of FILSPARI in IgA Nephropathy as Stock SoarsTravere Therapeutics, a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, has recently...

In a significant breakthrough for the treatment of IgA nephropathy (IgAN), Travere Therapeutics and CSL Vifor have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the...

Travere Therapeutics, a leading biopharmaceutical company, has recently entered into an exclusive licensing agreement with Renalys Pharma. This collaboration aims to develop and commercialize sparsentan, a breakthrough...

Travere Therapeutics, a leading biopharmaceutical company, has recently commenced a pivotal Phase 3 clinical trial for pegtibatinase, a potential groundbreaking treatment for classical Homocystinuria (HCU). This excitin...

Travere Therapeutics Inc recently conducted a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA) for FILSPARI in IgA nephropathy (IgAN). The meeting was fruitful, and as a result...